Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.49 |
| ▸ | PTGES | O14684 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | IAPP | P10997 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103445 | 1.00 | ALOX5 (0.49) | ALOX5PTGESPPARGGABRA1SIGMAR1 | |
| SCHEMBL3437103 | 1.00 | ALOX5 (0.49) | ALOX5PTGESPPARGGABRA1SIGMAR1 | |
| SCHEMBL6060200 | 0.89 | ALOX5 (0.49) | ALOX5PTGESPPARGAPEX1PSEN1 | |
| SCHEMBL2233170 | 0.84 | ALOX5 (0.50) | ALOX5PTGESPPARGAPEX1PTGS1 | |
| SCHEMBL2235010 | 0.83 | ALOX5 (0.47) | ALOX5PTGESPPARGAPEX1PSEN1 | |
| SCHEMBL6367461 | 0.81 | ALOX5 (0.54) | ALOX5PTGESPPARGAPEX1PTGS1 | |
| SCHEMBL31256756 | 0.78 | IAPP (0.60) | ALOX5PTGESPPARGCAPN1IAPP | |
| SCHEMBL5607169 | 0.76 | ALOX5 (0.52) | ALOX5PTGESPPARGAPEX1IAPP | |
| SCHEMBL1322605 | 0.76 | ALOX5 (0.52) | ALOX5PTGESPPARGAPEX1 | |
| SCHEMBL29741641 | 0.76 | ALOX5 (0.52) | ALOX5PTGESPPARGAPEX1IAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807720-B2 | Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2008147480-A2 | HYDROXAMIC ACID DERIVATIVES OF 3-PHENYL PROPIONIC ACIDS USEFUL AS THRAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | PAN THERA BIOPHARMA,LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188566-A1 | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning | ANTXR2, PAOX, AGXT | ALOX5 378/4885PTGES 433/4885PPARG 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.